Phase 1 Study of PF-08046033 in Advanced Solid Tumors
← catalyst calendarNCT07519655 · readout in 695 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
15
Countries
Puerto Rico, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-08 | actual | When the study began enrolling |
| Primary completion | 2028-07-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small-Cell Lung
- Esophageal Cancer
- Cutaneous Melanoma
Intervention
- Drug: PF-08046033
Primary outcomes
what the primary-completion date above is the date OFType, incidence and severity of participants with adverse events (AEs)
measured From the first day through 30-37 days after the last study treatment, up to approximately 1 year
Type, incidence, and severity of participants with laboratory abnormalities
measured From the first day through 30-37 days after the last study treatment, up to approximately 1 year
Number of participants with dose modifications
measured From the first day through 30-37 days after the last study treatment, up to approximately 1 year
Incidence of dose-limiting toxicities (DLTs)
measured From the first day through 30-37 days after the last study treatment, up to approximately 1 year
Recommended dose and schedule of PF-08046033 for expansion (RDE)
measured Up to 1 year
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed